|Videos|April 3, 2017

How to Be Smarter About Testing for C. difficile

Belinda Ostrowsky, MD, MPH, Health Systems Director of Epidemiology, Antimicrobial Stewardship & Infection Prevention, Montefiore Medical Center, and Associate Professor of Clinical Medicine, Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, explains how to be more sensible when it comes to testing for Clostridium difficile.

Belinda Ostrowsky, MD, MPH, Health Systems Director of Epidemiology, Antimicrobial Stewardship & Infection Prevention, Montefiore Medical Center, and Associate Professor of Clinical Medicine, Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, explains how to be more sensible when it comes to testing for Clostridium difficile.

Interview Transcript (slightly modified for readability)

“We don’t really have that many new tests for [Clostridium difficile], but I think what our session [at the Spring 2017 SHEA conference] was trying to discuss is to be more sensible about how we do our testing. We have this notion of antibiotic stewardship where we steward or guide people in the prescribing of antibiotics, but we can also steward people in the testing.

One of the issues is to make sure that we test the right patients. For example, for C. diff, many patients can be colonized, that could have the bacteria on them but not making them sick, and so, if we tested someone that doesn’t have the symptoms of C. diff, they may come up positive, it might force them to be isolated in their room by themselves, and be treated unnecessarily. [It’s important to have] criteria for which patients should be tested, making sure that they have diarrhea, that they’re not retested if they don’t need to be (that would put extra burden on the lab to do extra tests that are not needed), making sure, for example, that we don’t give a patient a laxative—which would promote diarrhea—and have it tested; it might come up positive for C. diff and it might be a falsely positive test.

The other side of that would be making sure that we do timely testing because a patient whose diagnosis is delayed is a patient where we don’t have the opportunity to really give them the appropriate treatment, [and] they may unnecessarily be spreading C. diff to other patients in the environment. So, I think the session was really about how we [can] be smarter about our testing in terms of choosing those patients [to test] and doing really timely testing.”


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.